03 March 2023 : Original article
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
Maha M. Islami
1CDE*, Mansoor Ahmed Khan 23ABCDEF, Mohammed A. Aseeri 23A, Majed A. Alshamrani 23E, Abdelmajid Alnatsheh 23ACDE, Sameer Alamoudi 34ADE, Ahmed A. Alzahrani 5E
DOI: 10.12659/AOT.938585
Ann Transplant 2023; 28:e938585
Table 3 engraftment results.
| Parameters | Zarzio® | Neupogen® | P value | |
|---|---|---|---|---|
| Autologous | Neutrophil engraftment | |||
| Filgrastim + chemotherapy | 10 | 11 | 0.83 | |
| Filgrastim | 10 | 10 | 0.657 | |
| Platelet engraftment | ||||
| Filgrastim + chemotherapy | 12 | 13 | 0.239 | |
| Filgrastim | 12 | 12 | 0.657 | |
| Allogeneic (patients) | Neutrophil engraftment | 13.5 | 14 | 0.62 |
| Platelet engraftment | 13.5 | 14 | 0.62 | |